Celyad Oncology Net Income

Celyad Oncology (CYAD) currently reports a net income of $-14M as of December 2024. That compares with $150K in the prior-year period — down 9743.2% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Celyad Oncology's net income history and peer comparisons.

Celyad Oncology's net income decreased from $150K to $-14M — a 9743.2% year-over-year decrease (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Celyad Oncology's net income of $-14M is lower than the Healthcare sector average of $16B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Celyad Oncology reported $-14M in net income as of December 2024. That compares with $150K in the prior-year period — down 9743.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-14M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Celyad Oncology, and consider following CYAD for alerts when major investors trade the stock.